Newsfeeds - Spark Newswire

1 minute read

News

Celsion Corporation Announces Company Name Change to Imunon, To Trade Under Symbol ‘IMNN’ Effective As Of Sept. 21

Today, 1:07 PM

Celsion Corporation (NASDAQ:CLSN), a clinical-stage drug development company, today announced a company name change to Imunon, Inc., reflecting the evolution of the Company's business focus and its

CLSN

3 minute read

Important Biotech Catalysts For September 15, 2022 – End Of The Day Summary

By Ragothaman Srinivasan

Today, 1:07 PM

Pfizer (NYSE:PFE) announced positive top-line results from the pivotal Phase 3 trial assessing the safety, tolerability, and immunogenicity…

ALNY

3 minute read

Celsion Completes Enrollment Of The Phase I/II OVATION 2 Study With GEN-1 In Advanced Ovarian Cancer

By Benzinga Newsdesk

Today, 1:07 PM

110 Patients Enrolled in Study Comparing Novel Gene-Mediated Immunotherapy plus Neoadjuvant Chemotherapy versus Neoadjuvant Chemotherapy Alone LAWRENCEVILLE, N.J., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Celsion

CLSN

2 minute read

Earnings

Celsion Earnings Perspective: Return On Capital Employed

By Benzinga Insights

Today, 1:07 PM

According to Benzinga Pro data, during Q2, Celsion (NASDAQ:CLSN) posted sales of $125 thousand. Earnings were up 42.31%, but Celsion still reported an overall loss of $6.04 million.

CLSN

9 minute read

Earnings

Earnings Scheduled For August 15, 2022

By Benzinga Insights

Today, 1:07 PM

Companies Reporting Before The Bell • Edible Garden (NASDAQ:EDBL) is likely to report earnings for its second quarter.

ABOS

3 minute read

Recap of Tuesday’s Biotech Catalysts – End of the Day Summary

By Ragothaman Srinivasan

Today, 1:07 PM

Ionis (NASDAQ: IONS) announced that Eplontersen met co-primary and secondary endpoints in interim analysis of the Phase 3 NEURO-TTRansform study for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) Ionis shares are trading low 4 percent at $35.10 in the after-hours session

ABBV

10 minute read

Earnings Scheduled For May 16, 2022

By Benzinga Insights

Today, 1:07 PM

Companies Reporting Before The Bell • AcelRx Pharmaceuticals (NASDAQ:ACRX) is estimated to report quarterly loss at $0.06 per share on revenue of $550.00 thousand.

ACRX

2 minute read

Movers

12 Health Care Stocks Moving In Thursday’s After-Market Session

By Benzinga Insights

Today, 1:07 PM

Gainers

ASLN

1 minute read

Celsion’s Formulated DNA Plasmid COVID-19 Vaccine Candidate Shows Activity Against Two Strains

By Vandana Singh

Today, 1:07 PM

Celsion Corporation (NASDAQ:CLSN) has presented its PLACCINE platform technology at the World Vaccine Congress. “PLACCINE is demonstrating the potential to be…

CLSN

1 minute read

12 Health Care Stocks Moving In Thursday’s Pre-Market Session

By Benzinga Insights

Today, 1:07 PM

BCDA